Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

被引：2

作者：

Graff, J. N. ^{[1
]}

Burotto, M. ^{[2
]}

Fong, P. C. ^{[3
]}

Pook, D. ^{[4
]}

Zurawski, B. ^{[5
]}

Kopp, R. Manneh ^{[6
]}

Salinas, J. E. ^{[7
]}

Bylow, K. ^{[8
,9
]}

Kramer, G. ^{[10
]}

Ratta, R. ^{[11
]}

Kwiatkowski, M. ^{[12
]}

Retz, M. ^{[13
]}

Kwak, C. ^{[14
]}

Arija, J. A. Arranz ^{[15
]}

Gurney, H. P. ^{[16
]}

Matsubara, N. ^{[17
]}

Liang, L. W. ^{[18
]}

Todoric, J. ^{[18
]}

Imai, K. ^{[18
]}

Stenzl, A. ^{[19
]}

机构：

[1] OHSU Oregon Hlth Sci Univ, Hematol Oncol Dept, Portland, OR USA

[2] Bradford Hill Clin Ctr, Med Oncol Dept, Recoleta, Chile

[3] Auckland City Hosp, Med Oncol Dept, Auckland, New Zealand

[4] Monash Hlth, Monash Med Ctr, Oncol Dept, Clayton, Vic, Australia

[5] Prof Franciszek Lukaszczyk Oncol Ctr, Oncol, Bydgoszcz, Poland

[6] Sociedad Oncol & Hematol Cesar, Dept Med Oncol, Valledupar, Colombia

[7] Hosp Prov Cordoba, Oncol, Cordoba, Spain

[8] Froedtert Hosp, Med Oncol, Milwaukee, WI USA

[9] Med Coll Wisconsin, Milwaukee, WI USA

[10] Med Univ Vienna, Urol, Vienna, Austria

[11] Hop Foch, Dept Med Oncol, Suresnes, France

[12] Szpital Wojewodzki Mikolaja Kopernika, Oddzial Dzienny Chemioterapii, Koszalin, Poland

[13] Tech Univ Munich, Rechts Isar Med Ctr, Urol, Munich, Germany

[14] Seoul Natl Univ, Coll Med, Urol, Yeongeon Med Campus, Seoul, South Korea

[15] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain

[16] Macquarie Univ, Med Oncol, Fac Med Hlth & Human Sci, Sydney, NSW, Australia

[17] Natl Canc Ctr Hosp East, Dept Med Oncol, Kashiwa, Chiba, Japan

[18] Merck Co Inc, Oncol, Rahway, NJ USA

[19] Univ Tubingen, Urol Dept, Crona Kliniken, Tubingen, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2721

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1771MO

引用

页码：S957 / S957

页数：1

共 50 条

[21] Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Petrylak, Daniel P.
Ratta, Raffaele
Matsubara, Nobuaki
Korbenfeld, Ernesto Pablo
Gafanov, Rustem
Mourey, Loic
Fer, Tilman Todenho Spacing Diaeresis
Gurney, Howard
Kramer, Gero
Bergman, Andre M.
Zalewski, Pawel
De Santis, Maria
Armstrong, Andrew J.
Gerritsen, Winald R.
Pachynski, Russell Kent
Saretsky, Todd L.
Ghate, Sameer R.
Li, Xin Tong
Schloss, Charles
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[22] Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
Yu, E. Y.
Park, S. H.
Goh, J. C. H.
Shin, S. J.
Mehra, N.
McDermott, R.
Sala Gonzalez, M. A.
Fong, P. C.
Greil, R.
Retz, M.
Sade, J. P.
Huang, Y-H.
Begbie, S.
Rey, F.
Kramer, G.
Suzuki, H.
Zhang, J.
Kim, J.
Poehlein, C. H.
Antonarakis, E. S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1163 - S1164
[23] Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
Massard, Christophe
Retz, Margitta
Hammerer, Peter
Quevedo, Fernando
Fong, Peter C. C.
Berry, William R.
Gurney, Howard
Piulats, Josep M.
Joshua, Anthony
Linch, Mark David
Kolinsky, Michael
Romano, Emanuela
Sridhar, Srikala S.
Conter, Henry Jacob
Augustin, Marinela
Wu, Haiyan
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[24] A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
Zhao, J. L.
Antonarakis, S.
Cheng, H.
George, D. J.
Aggarwal, R. R.
Abida, W.
Decker, B.
Smart-Curley, T.
Schonhoft, J.
Anderson, A.
Haywood, S.
Riedel, E.
Carver, B.
Wyatt, A.
Feng, F.
Knudsen, K.
Rathkopf, D. E.
ANNALS OF ONCOLOGY, 2021, 32 : S643 - S644
[25] Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
Sridhar, Srikala S.
Kolinsky, Michael Paul
Gravis, Gwenaelle
Mourey, Loic
Rodriguez, Jose Maria M. Piulats
Romano, Emanuela
Berry, William R.
Gurney, Howard
Retz, Margitta
Appleman, Leonard Joseph
Boegemann, Martin
De Bono, Johann S.
Joshua, Anthony M.
Emmenegger, Urban
Conter, Henry Jacob
Laguerre, Brigitte
Wu, Haiyan
Qiu, Ping
Schloss, Charles
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] KEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA- or ABI-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who had progression on chemotherapy (CTx)
Yu, E.
Xu, L.
Kim, J.
Antonarakis, E. S.
ANNALS OF ONCOLOGY, 2019, 30
[27] KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Yu, Evan Y.
Piulats, Josep M.
Gravis, Gwenaelle
Laguerre, Brigitte
Arija, Jose Angel Arranz
Oudard, Stephane
Fong, Peter C. C.
Kolinsky, Michael Paul
Augustin, Marinela
Feyerabend, Susan
Kam, Audrey E.
Gurney, Howard
Tafreshi, Ali
Retz, Margitta
Berry, William R.
Mar, Nataliya
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[28] KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Berry, William R.
Fong, Peter C. C.
Piulats, Josep M.
Appleman, Leonard Joseph
Conter, Henry Jacob
Feyerabend, Susan
Shore, Neal D.
Gravis, Gwenaelle
Laguerre, Brigitte
Gurney, Howard
Retz, Margitta
Romano, Emanuela
Mourey, Loic
De Bono, Johann S.
Kam, Audrey E.
Emmenegger, Urban
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[29] KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
De Bono, Johann S.
Goh, Jeffrey C. H.
Ojamaa, Kristiina
Rodriguez, Jose Maria Piulats
Drake, Charles G.
Hoimes, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[30] KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer
Petrylak, Daniel P.
Ratta, Raffaele
Gafanov, Rustem
Facchini, Gaetano
Piulats, Josep M.
Kramer, Gero
Flaig, Thomas W.
Chandana, Sreenivasa R.
Li, Ben
Burgents, Joseph
Fizazi, Karim
FUTURE ONCOLOGY, 2021, 17 (25) : 3291 - 3299

← 1 2 3 4 5 →